Wealthfront Advisers LLC Sells 45,803 Shares of Abbott Laboratories $ABT

Key Points

• Wealthfront Advisers LLC reduced its Abbott Laboratories stake by 28% in Q1, selling 45,803 shares and ending the quarter with 117,993 shares worth about $12.1 million.
• Abbott posted better-than-expected Q2 results, with adjusted EPS of $1.31 topping estimates, while revenue rose 13% year over year to $12.51 billion.
• The company also raised full-year 2026 EPS guidance to $5.45-$5.60 and maintained a quarterly dividend of $0.63 per share, implying a 2.6% annual yield.

Wealthfront Advisers LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 28.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 117,993 shares of the healthcare product maker's stock after selling 45,803 shares during the quarter. Wealthfront Advisers LLC's holdings in Abbott Laboratories were worth $12,114,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Brighton Jones LLC raised its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares in the last quarter. United Bank grew its position in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC increased its stake in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after acquiring an additional 292,547 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABT. Weiss Ratings raised shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, July 7th. Evercore reduced their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, April 17th. Mizuho dropped their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a research note on Friday, April 17th. Finally, The Goldman Sachs Group cut their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a report on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $117.61.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $98.81 on Friday. The company has a market capitalization of $172.11 billion, a PE ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61. The company has a 50-day simple moving average of $89.56 and a two-hundred day simple moving average of $102.18. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $12.51 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same period last year, the business earned $1.26 EPS. The company's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's payout ratio is currently 70.59%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 expectations with adjusted EPS of $1.31 versus $1.28 expected, showing better-than-expected profitability. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60, above its prior range, signaling confidence in earnings momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Revenue grew 13% year over year, supported by strong demand in medical devices, diagnostics, and emerging markets, which points to broad-based operating strength. Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Positive Sentiment: Heart-device demand and diagnostics growth, including a surge in sales tied to that segment, improved investor sentiment around Abbott’s longer-term growth profile. Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
• Neutral Sentiment: Abbott’s profit fell sharply from a year ago on a GAAP basis, but the decline was offset by stronger sales and guidance, making this more of a quality-over-headline-results story. Abbott Laboratories Sales Rise on Diagnostics Growth
• Negative Sentiment: Broader market and tech sell-off headlines may have slightly tempered enthusiasm, but they were not the main driver of ABT’s move. Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.